Compare Charles River Laboratories Intl. Inc (CRL) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Cronos Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B), while Cronos Group Inc trades at $3.07 (market cap $1.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 11.8× Cronos Group Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRL | CRON | |
|---|---|---|
Market Cap | $13.46B | $1.14B |
Sector | Health | Health |
52-Week High | $282.00 | $3.27 |
52-Week Low | $145.57 | $2.30 |
Enterprise Value | $16.30B | $341.13M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
